Dr. Robert S. Brown JR., MD
Hepatology (Hepatology Physician)
- Medicare participating
At a glance
- Medical school
- New York University School of Medicine (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 218
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: New York University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hepatology Physician primary
NY license 211334
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- New York-Presbyterian Hospital New York, NY
Medical groups
- Weill Medical College of Cornell (2,051 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 218
- Services billed
- 399
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 108 | 95 |
| Established patient office or other outpatient visit, 40-54 minutes | 48 | 44 |
| New patient office or other outpatient visit, 45-59 minutes | 31 | 31 |
| Measurement of liver stiffness | 17 | 17 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Carvedilol Other prescribers in New York, NY | 13 |
| Rosuvastatin Calcium Other prescribers in New York, NY | 13 |
| Tacrolimus Other prescribers in New York, NY | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 106 payments worth $176,545 in total to this clinician.
| Madrigal Pharmaceuticals | $51,898 |
|---|---|
| Gilead Sciences, Inc. | $38,100 |
| Ipsen Biopharmaceuticals, Inc | $27,080 |
| Mallinckrodt Hospital Products Inc. | $24,368 |
| Intercept Pharmaceuticals, Inc. | $10,780 |
| Bausch Health US, LLC | $9,552 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $5,600 |
| Mirum Pharmaceuticals, Inc. | $4,100 |
| Compensation for services other than consulting (speaking, faculty) | $125,934 |
|---|---|
| Consulting Fee | $32,430 |
| Travel and Lodging | $10,955 |
| Speaking at a medical education program | $3,720 |
| Food and Beverage | $3,506 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc May 31, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $11,520 |
| Madrigal Pharmaceuticals Dec 8, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $10,223 |
| Bausch Health US, LLC Feb 19, 2025 | Consulting Fee | $8,800 |
| Madrigal Pharmaceuticals Jan 17, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $7,755 |
| Gilead Sciences, Inc. Mar 13, 2025 | Compensation for services other than consulting (speaking, faculty) Epclusa · HCV Company’s description;3978825;GTF;10065208 | $6,190 |
| Mallinckrodt Hospital Products Inc. May 8, 2025 | Compensation for services other than consulting (speaking, faculty) TERLIVAZ · CRITICAL CARE | $5,520 |
| Mallinckrodt Hospital Products Inc. May 20, 2025 | Compensation for services other than consulting (speaking, faculty) TERLIVAZ · CRITICAL CARE | $5,520 |
| Mallinckrodt Hospital Products Inc. Nov 6, 2025 | Compensation for services other than consulting (speaking, faculty) TERLIVAZ · CRITICAL CARE | $5,520 |
| Mallinckrodt Hospital Products Inc. Dec 23, 2025 | Compensation for services other than consulting (speaking, faculty) TERLIVAZ · CRITICAL CARE | $5,520 |
| Gilead Sciences, Inc. Aug 22, 2025 | Consulting Fee Livdelzi · INFLAM Company’s description;4174370;VEM US;10065208 | $5,470 |
All 68 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Mallinckrodt Hospital Products Inc. Dec 23, 2025 | Compensation for services other than consulting (speaking, faculty) TERLIVAZ · CRITICAL CARE | $5,520 |
| Madrigal Pharmaceuticals Dec 19, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Ipsen Biopharmaceuticals, Inc Dec 18, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $5,049 |
| Madrigal Pharmaceuticals Dec 8, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $10,223 |
| Gilead Sciences, Inc. Nov 25, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to New York, NY · in-kind Company’s description;4260141;AHM;10065208 | $79.01 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC Nov 21, 2025 | Consulting Fee | $4,400 |
| Gilead Sciences, Inc. Nov 19, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4260540;AHM;10065208 | $3,790 |
| Mallinckrodt Hospital Products Inc. Nov 12, 2025 | Travel and Lodging TERLIVAZ · CRITICAL CARE · travel to NEW YORK, NY | $94.13 |
| Madrigal Pharmaceuticals Nov 10, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $4,935 |
| Gilead Sciences, Inc. Nov 10, 2025 | Compensation for services other than consulting (speaking, faculty) Vemlidy · HBV Company’s description;4262256;AHM;10065208 | $2,370 |
| Mallinckrodt Hospital Products Inc. Nov 6, 2025 | Compensation for services other than consulting (speaking, faculty) TERLIVAZ · CRITICAL CARE | $5,520 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC Nov 5, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,200 |
| Madrigal Pharmaceuticals Oct 7, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $4,935 |
| Madrigal Pharmaceuticals Oct 7, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to AVON, CT · in-kind | $1,433 |
| Madrigal Pharmaceuticals Sep 27, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Madrigal Pharmaceuticals Sep 27, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to MORRISTOWN, NJ · in-kind | $657 |
| Madrigal Pharmaceuticals Sep 13, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Gilead Sciences, Inc. Sep 12, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4178373;AHM;10065208 | $4,930 |
| Gilead Sciences, Inc. Sep 12, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Albany, NY · in-kind Company’s description;4327551;AHM;10065208 | $1,545 |
| Gilead Sciences, Inc. Sep 12, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Chicago, IL Company’s description;4174527;VEM US;10065208 | $175 |
| Gilead Sciences, Inc. Sep 12, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Chicago, IL Company’s description;4174520;VEM US;10065208 | $149 |
| Gilead Sciences, Inc. Aug 22, 2025 | Consulting Fee Livdelzi · INFLAM Company’s description;4174370;VEM US;10065208 | $5,470 |
| Gilead Sciences, Inc. Aug 15, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Chicago, IL · in-kind Company’s description;4174493;VEM US;10065208 | $128 |
| Gilead Sciences, Inc. Aug 14, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Chicago, IL · in-kind Company’s description;4174499;VEM US;10065208 | $387 |
| Gilead Sciences, Inc. Aug 14, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Chicago, IL · in-kind Company’s description;4174500;VEM US;10065208 | $281 |
| Gilead Sciences, Inc. Aug 14, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Chicago, IL · in-kind Company’s description;4174313;VEM US;10065208 | $172 |
| Madrigal Pharmaceuticals Aug 13, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $4,935 |
| GlaxoSmithKline, LLC. Aug 12, 2025 | Consulting Fee | $800 |
| Gilead Sciences, Inc. Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) Epclusa · HCV Company’s description;4114128;AHM;10065208 | $2,370 |
| Madrigal Pharmaceuticals Jul 18, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to DALLAS, TX · in-kind | $146 |
| Genentech USA, Inc. Jul 17, 2025 | Consulting Fee Ocrevus · Immunology | $2,625 |
| Ipsen Biopharmaceuticals, Inc Jun 30, 2025 | Compensation for services other than consulting (speaking, faculty) Bylvay · Gastroenterology | $2,754 |
| Ipsen Biopharmaceuticals, Inc Jun 30, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $2,754 |
| Mirum Pharmaceuticals, Inc. Jun 18, 2025 | Consulting Fee | $3,000 |
| Mirum Pharmaceuticals, Inc. Jun 18, 2025 | Travel and Lodging travel to Amsterdam, Netherlands | $373 |
| Mirum Pharmaceuticals, Inc. Jun 18, 2025 | Travel and Lodging travel to Amsterdam, Netherlands | $319 |
| Mallinckrodt Hospital Products Inc. Jun 4, 2025 | Travel and Lodging TERLIVAZ · CRITICAL CARE · travel to NEW YORK, NY | $71.63 |
| Ipsen Biopharmaceuticals, Inc May 31, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $11,520 |
| Ipsen Biopharmaceuticals, Inc May 31, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Dallas, TX · in-kind | $636 |
| Ipsen Biopharmaceuticals, Inc May 31, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Dallas, TX · in-kind | $203 |
| Mallinckrodt Hospital Products Inc. May 20, 2025 | Compensation for services other than consulting (speaking, faculty) TERLIVAZ · CRITICAL CARE | $5,520 |
| Intercept Pharmaceuticals, Inc. May 13, 2025 | Speaking at a medical education program OCALIVA · Hepatology / Gastroenterology | $3,720 |
| Mallinckrodt Hospital Products Inc. May 13, 2025 | Travel and Lodging TERLIVAZ · CRITICAL CARE · travel to NEW YORK, NY | $58.81 |
| Mallinckrodt Hospital Products Inc. May 8, 2025 | Compensation for services other than consulting (speaking, faculty) TERLIVAZ · CRITICAL CARE | $5,520 |
| Intercept Pharmaceuticals, Inc. May 2, 2025 | Consulting Fee OCALIVA · Hepatology / Gastroenterology | $1,860 |
| Intercept Pharmaceuticals, Inc. May 2, 2025 | Consulting Fee OCALIVA · Hepatology / Gastroenterology | $155 |
| Gilead Sciences, Inc. Apr 22, 2025 | Compensation for services other than consulting (speaking, faculty) Vemlidy · HBV Company’s description;4115990;AHM;10065208 | $3,790 |
| Madrigal Pharmaceuticals Apr 15, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $3,878 |
| Madrigal Pharmaceuticals Apr 15, 2025 | Travel and Lodging REZDIFFRA · LIVER DISEASE · travel to SMITHTOWN, NY · in-kind | $881 |
| Mallinckrodt Hospital Products Inc. Mar 25, 2025 | Compensation for services other than consulting (speaking, faculty) TERLIVAZ · CRITICAL CARE | $1,380 |
| Gilead Sciences, Inc. Mar 20, 2025 | Travel and Lodging Epclusa · HCV · travel to Atlanta, GA Company’s description;4027011;GTF;10065208 | $211 |
| GlaxoSmithKline, LLC. Mar 18, 2025 | Consulting Fee | $1,600 |
| Gilead Sciences, Inc. Mar 13, 2025 | Compensation for services other than consulting (speaking, faculty) Epclusa · HCV Company’s description;3978825;GTF;10065208 | $6,190 |
| Gilead Sciences, Inc. Mar 11, 2025 | Travel and Lodging Epclusa · HCV · travel to New York, NY · in-kind Company’s description;4129203;AHM;10065208 | $92.60 |
| Gilead Sciences, Inc. Mar 7, 2025 | Compensation for services other than consulting (speaking, faculty) Epclusa · HCV Company’s description;4113542;AHM;10065208 | $3,790 |
| Gilead Sciences, Inc. Mar 1, 2025 | Travel and Lodging Epclusa · HCV · travel to Atlanta, GA · in-kind Company’s description;4027088;GTF;10065208 | $358 |
| Gilead Sciences, Inc. Mar 1, 2025 | Travel and Lodging Epclusa · HCV · travel to Atlanta, GA · in-kind Company’s description;4026837;GTF;10065208 | $350 |
| Gilead Sciences, Inc. Mar 1, 2025 | Travel and Lodging Epclusa · HCV · travel to Atlanta, GA · in-kind Company’s description;4026834;GTF;10065208 | $284 |
| Bausch Health US, LLC Feb 19, 2025 | Consulting Fee | $8,800 |
| Bausch Health US, LLC Feb 19, 2025 | Travel and Lodging travel to Bridgewater, NJ · in-kind | $331 |
| Bausch Health US, LLC Feb 19, 2025 | Travel and Lodging travel to Bridgewater, NJ · in-kind | $296 |
| Ipsen Biopharmaceuticals, Inc Feb 8, 2025 | Compensation for services other than consulting (speaking, faculty) IQIRVO · Rare Disease | $3,672 |
| Intercept Pharmaceuticals, Inc. Feb 3, 2025 | Consulting Fee OCALIVA · Hepatology / Gastroenterology | $3,720 |
| Intercept Pharmaceuticals, Inc. Feb 3, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to Dallas, TX | $726 |
| Intercept Pharmaceuticals, Inc. Feb 3, 2025 | Travel and Lodging OCALIVA · Hepatology / Gastroenterology · travel to Dallas, TX · in-kind | $449 |
| Madrigal Pharmaceuticals Jan 17, 2025 | Compensation for services other than consulting (speaking, faculty) REZDIFFRA · LIVER DISEASE | $7,755 |
| Mallinckrodt Hospital Products Inc. Jan 8, 2025 | Travel and Lodging TERLIVAZ · CRITICAL CARE · travel to NEW YORK, NY | $65.10 |
| Mallinckrodt Hospital Products Inc. Jan 8, 2025 | Travel and Lodging TERLIVAZ · CRITICAL CARE · travel to NEW YORK, NY | $2.90 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $16,908 in research payments for these studies, mostly to the institutions running them.
- Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)
AbbVie Inc. · Completed · NCT04903626
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.